BRPI0308706B8 - hidrato de darifenacina, e processo para sua preparação - Google Patents

hidrato de darifenacina, e processo para sua preparação

Info

Publication number
BRPI0308706B8
BRPI0308706B8 BRPI0308706A BR0308706A BRPI0308706B8 BR PI0308706 B8 BRPI0308706 B8 BR PI0308706B8 BR PI0308706 A BRPI0308706 A BR PI0308706A BR 0308706 A BR0308706 A BR 0308706A BR PI0308706 B8 BRPI0308706 B8 BR PI0308706B8
Authority
BR
Brazil
Prior art keywords
bladder
urinary
hydrate
treatment
receptor antagonist
Prior art date
Application number
BRPI0308706A
Other languages
English (en)
Other versions
BR0308706A (pt
BRPI0308706B1 (pt
Inventor
O'oconnor Garry
George Matthews John
James Dunn Peter
Jack Newbury Trevor
Original Assignee
Aspen Global Incorporated
Novartis Int Pharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9933731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0308706(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aspen Global Incorporated, Novartis Int Pharmaceutical Ltd filed Critical Aspen Global Incorporated
Publication of BR0308706A publication Critical patent/BR0308706A/pt
Publication of BRPI0308706B1 publication Critical patent/BRPI0308706B1/pt
Publication of BRPI0308706B8 publication Critical patent/BRPI0308706B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"hidrato estável de um antagonista de receptor muscarínico". a presente invenção refere-se a um hidrato sólido estável de um antagonista de receptor muscarínico que é útil no tratamento de síndrome de intestino irritável, doença diverticular, acalasia esofageal, doença de vias aéreas obstrutivas crônica, bexiga super ativa incluindo sintomas de incontinência, urgência e freqüência, incontinência urinária, urgência urinária neurogênica ou polaquiúria, tratamento de distúrbio funcional de bexiga, vazamento urinário, micção difícil ou dolorosa causada por bexiga neurogênica, bexiga hipertônica ou espástica, síndrome de bexiga disfuncional, distúrbios gastrointestinais incluindo hiperatividade gastrointestinal, e efeito relaxante sobre células de músculo liso.
BRPI0308706A 2002-03-26 2003-03-17 hidrato de darifenacina, e processo para sua preparação BRPI0308706B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0207104.1A GB0207104D0 (en) 2002-03-26 2002-03-26 Stable hydrate of a muscarinic receptor antagonist
GB0207104.1 2002-03-26
PCT/IB2003/001043 WO2003080599A1 (en) 2002-03-26 2003-03-17 Stable hydrate of a muscarinic receptor antagonist

Publications (3)

Publication Number Publication Date
BR0308706A BR0308706A (pt) 2005-01-04
BRPI0308706B1 BRPI0308706B1 (pt) 2018-07-10
BRPI0308706B8 true BRPI0308706B8 (pt) 2021-05-25

Family

ID=9933731

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122018000397A BR122018000397B8 (pt) 2002-03-26 2003-03-17 solvato de darifenacina, e processo para sua preparação
BRPI0308706A BRPI0308706B8 (pt) 2002-03-26 2003-03-17 hidrato de darifenacina, e processo para sua preparação

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122018000397A BR122018000397B8 (pt) 2002-03-26 2003-03-17 solvato de darifenacina, e processo para sua preparação

Country Status (22)

Country Link
US (3) US6930188B2 (pt)
EP (2) EP1490357B1 (pt)
JP (2) JP2005524678A (pt)
KR (4) KR20100101182A (pt)
CN (1) CN100345840C (pt)
AR (1) AR042608A1 (pt)
AT (1) ATE495169T1 (pt)
AU (1) AU2003209921A1 (pt)
BR (2) BR122018000397B8 (pt)
CA (1) CA2480287C (pt)
CY (2) CY1111200T1 (pt)
DE (1) DE60335711D1 (pt)
DK (2) DK2336124T3 (pt)
ES (2) ES2394067T3 (pt)
GB (1) GB0207104D0 (pt)
PA (1) PA8569701A1 (pt)
PT (2) PT1490357E (pt)
SI (2) SI1490357T1 (pt)
SV (1) SV2003001515A (pt)
TW (1) TW200306816A (pt)
UY (1) UY27735A1 (pt)
WO (1) WO2003080599A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
BRPI0609952A2 (pt) * 2005-04-24 2010-05-11 Wyeth Corp métodos para modular a função da bexiga
EP1877393A2 (en) * 2005-12-27 2008-01-16 Teva Pharmaceutical Fine Chemicals S.R.L. Processes for preparing darifenacin hydrobromide
EP2109601A2 (en) * 2007-01-05 2009-10-21 Dr. Reddy's Laboratories Ltd. Preparation of darifenacin and its salts
KR101495708B1 (ko) * 2007-02-23 2015-02-25 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 무스카린 수용체 안타고니스트로 유용한 4차 암모늄 디페닐메틸 화합물
US20090005309A1 (en) * 2007-05-18 2009-01-01 Auspex Pharmaceuticals, Inc. Substituted piperidines
US20100204296A1 (en) * 2007-06-08 2010-08-12 Actavis Group Ptc Ehf Novel Polymorphs of Darifenacin Free Base and its Hydrobromide Salt
WO2009006413A1 (en) * 2007-06-30 2009-01-08 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
WO2009010846A2 (en) * 2007-07-13 2009-01-22 Medichem, S.A. Amorphous form of darifenacin hydrobromide and processes for the preparation thereof
CZ200845A3 (cs) * 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
WO2009125426A2 (en) * 2008-02-08 2009-10-15 Neuland Laboratories Ltd NOVEL PROCESS FOR THE PREPARATION OF (3SM-[2-(2 J-DIHYDRO-5- BENZOFURANYLϊETHYL]-α.α -DIPHENYL-3-PYRROLIDINEACETAMIDE HYDROBROMIDE
CN101983187A (zh) 2008-04-02 2011-03-02 株式会社钟化 (s)-3-(1-氰基-1，1-二苯基甲基)吡咯烷的制备方法
WO2010032225A2 (en) * 2008-09-22 2010-03-25 Watson Pharma Private Limited Process for preparation of darifenacin and intermediates used in the process
EP2236509A1 (en) 2009-04-01 2010-10-06 Ragactives, S.L. Method for obtaining 1,3-difunctionalized pyrrolidine derivatives
WO2011070419A1 (en) 2009-12-10 2011-06-16 Aurobindo Pharma Limited An improved process for the preparation of darifenacin hydrobromide
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
KR20180094965A (ko) * 2015-12-14 2018-08-24 아이언우드 파마슈티컬스, 인코포레이티드 위장 괄약근 기능장애의 치료를 위한 sGC 자극제의 용도
EP3497075B1 (de) * 2016-08-12 2020-08-05 Bayer CropScience Aktiengesellschaft Verfahren zur herstellung von substituierten styrol-derivaten
JP7285259B2 (ja) * 2017-09-12 2023-06-01 エルテーエス ローマン テラピー－ジステーメ アーゲー イオントフォレーシス用マイクロニードルデバイス

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906166D0 (en) 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
US5233053A (en) * 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9400600D0 (en) * 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9612710D0 (en) * 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment
EP0927034A1 (en) * 1996-09-19 1999-07-07 American Home Products Corporation Method of treating urinary incontinence
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist

Also Published As

Publication number Publication date
DK2336124T3 (da) 2012-12-17
BR0308706A (pt) 2005-01-04
CN100345840C (zh) 2007-10-31
KR20040093477A (ko) 2004-11-05
CN1642945A (zh) 2005-07-20
CA2480287C (en) 2011-05-31
JP2005524678A (ja) 2005-08-18
BRPI0308706B1 (pt) 2018-07-10
AR042608A1 (es) 2005-06-29
US20080167367A1 (en) 2008-07-10
EP1490357A1 (en) 2004-12-29
BR122018000397B1 (pt) 2019-07-02
TW200306816A (en) 2003-12-01
UY27735A1 (es) 2003-10-31
ES2358644T3 (es) 2011-05-12
HK1080847A1 (zh) 2006-05-04
US20030191176A1 (en) 2003-10-09
CY1111200T1 (el) 2015-06-11
SI1490357T1 (sl) 2011-05-31
KR101026283B1 (ko) 2011-03-31
DE60335711D1 (de) 2011-02-24
PA8569701A1 (es) 2003-12-10
KR20110130539A (ko) 2011-12-05
EP2336124A1 (en) 2011-06-22
KR20120098888A (ko) 2012-09-05
US6930188B2 (en) 2005-08-16
SI2336124T1 (sl) 2012-12-31
WO2003080599A1 (en) 2003-10-02
ATE495169T1 (de) 2011-01-15
GB0207104D0 (en) 2002-05-08
PT1490357E (pt) 2011-03-01
KR20100101182A (ko) 2010-09-16
CA2480287A1 (en) 2003-10-02
JP2010195828A (ja) 2010-09-09
KR101212908B1 (ko) 2012-12-14
PT2336124E (pt) 2012-12-12
US7696357B2 (en) 2010-04-13
BR122018000397B8 (pt) 2021-07-27
DK1490357T3 (da) 2011-04-04
EP2336124B1 (en) 2012-08-29
EP1490357B1 (en) 2011-01-12
ES2394067T3 (es) 2013-01-16
US20050245597A1 (en) 2005-11-03
SV2003001515A (es) 2003-12-15
HK1156626A1 (en) 2012-06-15
AU2003209921A1 (en) 2003-10-08
CY1113433T1 (el) 2016-06-22

Similar Documents

Publication Publication Date Title
BR122018000397B8 (pt) solvato de darifenacina, e processo para sua preparação
BRPI0509298A (pt) composto, composição farmacêutica, métodos de inibir receptor h3 de histamina em um mamìfero, para tratar ou prevenir um distúrbio do sistema nervoso, obesidade, e um distúrbio ou doença, e, uso de um composto
BR0104830A (pt) Tratamento de combinação para a demência ou déficits cognitivos associados com a doença de alzheimer e com a doença de parkinson
EP1993365A4 (en) BIOLOGICALLY AVAILABLE CURCUMINOID FORMULATIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER DISEASES RELATED TO THE AGE
JP2003516325A5 (pt)
WO2008002621A3 (en) Benzyl-substituted quinolone m1 receptor positive allosteric modulators
MA30556B1 (fr) COMPOSES A BASE DE DIALKYLPHENYLE AYANT UNE ACTIVITE AGONISTE DU RECEPTEUR ADRENERGIQUE ß2 ET ANTAGONISTE DU RECEPTEUR MUSCARINIQUE.
EA200970451A1 (ru) Новые производные триазиндионов в качестве модуляторов рецептора гамк
MX2009006747A (es) Formulacion farmaceutica que comprende un antagonista de neurocinina.
Shaw et al. Originals and Papers
US20060173052A1 (en) Use of the non-opiate analgesic drug flupirtine of the treatment of overactive bladder and associated diseases including urge incontinence, urinary flow problems as a result of prostate hyperplasia and irritable bowl syndrome
TW200914022A (en) Synergistic combinations
US11458142B2 (en) Compositions and methods for ameliorating pain
NO20064050L (no) Anvendelse av agomelatin for a oppna medikamenter tiltenkt for behandlingen av sovnforstyrrelser i den deprimerte pasient
CY1111783T1 (el) Θεραπεια συνδυασμου διαταραχων κατωτερης ουροποιητικης οδου με 2 προσδεματα και μη στεροειδες αντιφλεγμονωδες φαρμακο
EA200801488A1 (ru) Замещенные фенетиламины, обладающие серотонинергической и/или норэпинефринергической активностью
WO2009064836A3 (en) Kynurenine-aminotransferase inhibitors
RU2005125047A (ru) Соединения карбоновых кислот
BRPI0920492A2 (pt) uso de deferiprona para o tratamento e prevenção de doenças oftalmológicas relacionadas ao ferro.
WO2008037045A3 (en) Composition containing a mixture of antidepressants for treating premature ejaculation.
Fernández-Jorge et al. Consort photocontact dermatitis from piketoprofen.
Pai et al. Accessory brachialis muscle: a case report
Wanajo et al. Ureteral selectivity of intravenous β-adrenoceptor agonists in pig model of acute ureteral obstruction: comparison of KUL-7211, a selective β2/β3 agonist, with isoproterenol, terbutaline, and CL-316243
TWI324513B (en) New association between agomelatine and a noradrenaline reuptake inhibitor, and pharmaceutical compositions containing it
JP5564263B2 (ja) ムスカリンｍ１、ｍ２およびｍ３受容体の選択的阻害を有する薬剤の製造のための１０−［（３ｒ）−１−アザビシクロ［２．２．２］オクト−３−イルメチル］−１０ｈ−フェノチアジンの使用

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: ASPEN GLOBAL INCORPORATED (MR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25G Requested change of headquarter approved

Owner name: ASPEN GLOBAL INCORPORATED (MR)

B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B17A Notification of administrative nullity (patentee has 60 days time to reply to this notification)

Free format text: REQUERENTE DA NULIDADE: ZODIAC PRODUTOS FARMACEUTICOS S.A. - PETICAO NO870190002945 DE 10/01/2019.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/03/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 17/03/2023